Zentalis Pharmaceuticals Inc (NAS:ZNTL)
$ 11.75 -0.32 (-2.65%) Market Cap: 834.40 Mil Enterprise Value: 412.18 Mil PE Ratio: 0 PB Ratio: 1.82 GF Score: 38/100

Zentalis Pharmaceuticals Inc To Host Investor Call Transcript

Jun 06, 2023 / 12:00PM GMT
Release Date Price: $25.14 (+1.86%)
Operator

Welcome to the Zentalis Pharmaceuticals' Azenosertib Clinical Update Call. (Operator Instructions) As a reminder, this event is being recorded.

I will now hand the call over to Adam Levy, Senior Vice President, Investor Relations at Zentalis. Thank you. You may begin.

Adam Levy
Zentalis Pharmaceuticals, Inc. - SVP of IR

Good morning. Thank you for joining us today for our Azenosertib Clinical Update Call.

Before we begin, I'd like to take care of a few housekeeping items. I invite you to visit the Investors section of our website to view the webcast slides, today's press release on our azenosertib monotherapy dose optimization data and our May 25 press release on our azenosertib plus chemotherapy combination data, which was also presented yesterday at ASCO as Abstract 5513.

During today's presentation, we will be making forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. Additional information

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot